Collinson, F; Qian, W; Fossati, R; Lissoni, A; Williams, C; Parmar, M; Ledermann, J; ... on behalf of the ICON1 collaborators; + view all Collinson, F; Qian, W; Fossati, R; Lissoni, A; Williams, C; Parmar, M; Ledermann, J; Colombo, N; Swart, A; on behalf of the ICON1 collaborators; - view fewer (2014) Optimal treatment of early-stage ovarian cancer. Ann Oncol , 25 (6) pp. 1165-1171. 10.1093/annonc/mdu116.

Preview

PDF Ann_Oncol-2014-Collinson-1165-71.pdf Download (242kB)

Abstract

There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International Collaborative Ovarian Neoplasm (ICON)1 trial demonstrated benefit in both overall survival (OS) and recurrence-free survival (RFS) with adjuvant chemotherapy. We report results of 10-year follow-up to establish whether benefits are maintained longer-term and discuss how this and other available evidence from randomised trials can be used to guide treatment options regarding the need for, and choice of, adjuvant chemotherapy regimen.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item